Early effects of ozoralizumab 30 mg in patients with rheumatoid arthritis and inadequate response to methotrexate: a post hoc trajectory analysis of the phase II/III OHZORA trial
Authors' conclusion
OZR 30 mg demonstrated both immediate and sustained efficacy in MTX-IR patients with RA.
Study context
- Population
- Patients with rheumatoid arthritis (RA) and inadequate response to MTX (MTX-IR) from the OHZORA trial, initiated on ozoralizumab (OZR) 30 mg
- Participants
- 141 patients
- Primary endpoint
- Rate of achieving LDA by CDAI 3 days post-OZR initiation
- Follow-up
- 3 days
Methodological detailstrajectory analysis, growth mixture modelling, multiple logistic regression
- Trajectory analysis
- Growth mixture modelling
- Multiple logistic regression
Primary result
As reported in the abstract
LDA by CDAI · day 3 after OZR initiation
Low disease activity (LDA) achievement rate (n=18)
12.8%
Further findings
Improved to LDA by Clinical Disease Activity Index (CDAI) · up to week 52
- Improved to LDA (n=100)
- 70.9%
Retention rate of OZR · up to 52 weeks
- Retention rate (n=124)
- 87.9%
CDAI trajectories by growth mixture modelling (GMM)
- Three distinct groups identified; one group reached LDA within 4 weeks and maintained LDA up to week 52 (n)
- 78
Predictors of early sustained LDA group membership (multiple logistic regression)
- Low baseline C-reactive protein (CRP) and low CDAI independently associated with group membership
Original publication
Early effects of ozoralizumab 30 mg in patients with rheumatoid arthritis and inadequate response to methotrexate: a post hoc trajectory analysis of the phase II/III OHZORA trial. RMD Open. Published 19 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →